The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2015/04/01
-
Journal
-
Indian UGC (journal)
-
Refrences91
-
Citations402
-
Kathleen M. Mahoney
-
Gordon J. Freeman
-
David F. McDermott
Cite
Mahoney, Kathleen M., et al. “The Next Immune-Checkpoint Inhibitors: PD-1 PD-L1 Blockade in Melanoma”. Clinical Therapeutics, vol. 37, no. 4, 2015, pp. 764-82, https://doi.org/10.1016/j.clinthera.2015.02.018.
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 37(4), 764-782. https://doi.org/10.1016/j.clinthera.2015.02.018
Mahoney, Kathleen M., Gordon J. Freeman, and David F. McDermott. “The Next Immune-Checkpoint Inhibitors: PD-1 PD-L1 Blockade in Melanoma”. Clinical Therapeutics 37, no. 4 (2015): 764-82. https://doi.org/10.1016/j.clinthera.2015.02.018.
Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics. 2015;37(4):764-82.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- Clinical consequences of polypharmacy in elderly
- Long-term side effects of glucocorticoids
- Paclitaxel: a review of adverse toxicities and novel delivery strategies
- Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Nivolumab in previously untreated melanoma without BRAF mutation | New England Journal of Medicine |
| 2015 | |
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation | Nature Communications |
| 748 | 2015 |
| The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | Current Opinion in Immunology |
| 243 | 2015 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Nature |
| 1,762 | 2014 |
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Nature |
| 3,707 | 2014 |
Refrences Analysis
The category
Medicine: Medicine (General) 31
is the most frequently represented among the references in this article. It primarily includes studies from New England Journal of Medicine The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Optimization of chemotherapy regimens using mathematical programming | Computers & Industrial Engineering |
| 1 | 2024 |
| NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1 | Drug Resistance Updates |
| 2024 | |
| Development of a microcantilever-based biosensor for detecting Program Death Ligand 1 | Saudi Pharmaceutical Journal |
| 2024 | |
The ‘Other’ subfamily of HECT E3 ubiquitin ligases evaluate the tumour immune microenvironment and prognosis in patients with hepatocellular carcinoma | IET Systems Biology |
| 2024 | |
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials | Therapeutic Advances in Medical Oncology |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 165
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells and was published in 2015. The most recent citation comes from a 2024 study titled Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model. This article reached its peak citation in 2017, with 57 citations. It has been cited in 262 different journals, 23% of which are open access. Among related journals, the Frontiers in Immunology cited this research the most, with 21 citations. The chart below illustrates the annual citation trends for this article.